

Karyopharm Therapeutics Inc.
 Form 4
 July 25, 2014

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Plio Ltd

2. Issuer Name and Ticker or Trading Symbol
 Karyopharm Therapeutics Inc.
 [KPTI]

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)

(Last) (First) (Middle)
 SIMOU MENARDOU 8,, RIA
 COURT 8, OFFICE 101
 (Street)

3. Date of Earliest Transaction
 (Month/Day/Year)
 07/23/2014

___ Director ___X___ 10% Owner
 ___ Officer (give title below) ___X___ Other (specify below)
 Former 10% Owner (exit filing)

6015 LARNACA, G4

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 ___ Form filed by One Reporting Person
 ___X___ Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|--|
| | | | | Code V Amount (D) Price | | | |
| COMMON STOCK | 07/23/2014 | | S | 500,000 A \$ 35.5437 | 2,693,473 (1) | D (1) (2) (3) | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Karyopharm Therapeutics Inc. - Form 4

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Owned Following Transaction (Instr. 5) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|---------|--------------------------------|
| | Director | 10% Owner | Officer | Other |
| Plio Ltd SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101 6015 LARNACA, G4 | | X | | Former 10% Owner (exit filing) |
| Czernik Marcin SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101 6015 LARNACA, G4 | | X | | |
| Hadjimichael Andreas SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101 6015 LARNACA, G4 | | X | | |
| Hadjimichael Amalia SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101 6015 LARNACA, G4 | | X | | |
| Jankilevitsch Gregory CHALET LE REFUGE CHEMIN DE JOLIMONT 18 VILLARS-SUR-OLLON, V8 CH-1884 | | | | Former 10% Owner (exit filing) |

Signatures

/s/ Plio Limited, by /s/ Simon Prisk, as attorney-in fact by power of attorney 07/25/2014
**Signature of Reporting Person Date

/s/ Marcin Czernik, by /s/ Simon Prisk, as attorney-in fact by power of attorney 07/25/2014
**Signature of Reporting Person Date

07/25/2014

Edgar Filing: Karyopharm Therapeutics Inc. - Form 4

/s/ Andreas Hadjimichael, by /s/ Simon Prisk, as attorney-in fact by power of attorney

__Signature of Reporting Person

Date

/s/ Amalia Hadjimichael, by /s/ Simon Prisk, as attorney-in fact by power of attorney

07/25/2014

__Signature of Reporting Person

Date

/s/ Gregory Jankilevitsch, by /s/ Simon Prisk, as attorney-in fact by power of attorney

07/25/2014

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Shares of Common Stock are owned directly by Plio Limited ("Plio"). Plio's directors, Marcin Czernik, Andreas Hadjimichael and Amalia Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Plio. Gregory Jankilevitsch, the sole shareholder of Plio, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Plio. The shares owned by Plio do not include the 10,258,079 shares of the issuer's Common Stock held by Chione Limited, which has the same directors as Plio.
- (1) Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.
- (2) Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.
- (3)

Remarks:

Exhibit Index Exhibit 24.1 - Power of Attorney, dated November 5, 2013, made by Marcin Czernik and Plio Limited in favor of

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.